ArticleAnnals of work exposures and health2025
Development of exposure limits for sodium fluoroacetate based on chronic health effects.
Article in Annals of work exposures and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium fluoroacetate, better known as 1080, is a vertebrate toxin used for predator elimination in New Zealand. Sodium fluoroacetate itself is non-toxic but is readily converted by the body into highly toxic fluorocitrate, a metabolic poison known to impair mitochondrial function through inhibition of the enzyme aconitase, a key step in the citric acid cycle. The New Zealand workplace exposure standard of 0.05 mg/m3 is unlikely to protect workers from chronic exposure health risks. The chronic protective airborne exposure limit presented herein was derived from a NOAEL of 0.075 mg/kg/day via application of an uncertainty factor of 3,000. A UF of 3,000 was chosen based on 3 for toxicodynamic differences between species; 10 for intraspecies variation; 10 for extrapolation from a short-term duration study; and 10 for database limitations. The resulting reference dose of 0.025 µg/kg/day was converted to an inhalable 8-h equivalent TWA assuming a conservative 60 kg person and a ventilation rate during medium metabolic activity of 6 L/min. This gave a workplace exposure limit for sodium fluoroacetate of 0.52 µg/m3, which should be protective of chronic health risk resulting from quantal myocardial and testicular toxicity. A corresponding BEI of 0.15 µg/L was derived using methodology previously described by Beasley et al. (2009).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.